COMT Inhibitors for Impulse Control Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Impulse control disorders, such as pathological gambling, kleptomania, and substance addictions, are refractory to existing pharmacological and psychotherapeutic treatments, necessitating the development of effective therapeutic agents.
Innovation Solution
Administration of catechol-O-methyl-transferase inhibitors (COMT inhibitors) like tolcapone or entacapone, which regulate dopamine levels in the prefrontal cortex, improving executive functioning and decision-making by enhancing prefrontal cortex dopamine, thereby treating impulse control disorders and substance addictions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmacological and psychotherapeutic treatments are used for impulse control disorders, then treatment coverage is provided, but treatment effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by introducing a novel pharmacological mechanism (COMT inhibition) that differs from existing treatments. By targeting the catechol-O-methyl-transferase enzyme and modifying dopamine metabolism parameters, the invention achieves therapeutic effects in treatment-resistant impulse control disorders where conventional approaches have failed
Solution Approach 2:
The patent uses COMT inhibitors as an intermediary substance to mediate between the dysregulated dopamine system and the pathological impulses. The drug acts as a chemical mediator that modulates dopamine availability in the prefrontal cortex, thereby indirectly controlling impulsive behaviors without directly addressing the underlying disorder
2Adaptability or versatility
If psychotherapy and behavior modification are applied, then comprehensive treatment approach is achieved, but clinical success rate remains low
Solution Approach 1:
The patent merges pharmacological intervention with the existing psychotherapeutic framework. By combining COMT inhibitor medication with psychotherapy and behavior modification, the treatment achieves both biological and psychological components, creating a comprehensive approach that addresses both neurochemical imbalances and behavioral patterns
3Adaptability or versatility
If varied pharmaceutical preparations are administered, then multiple treatment options are available, but therapeutic efficacy is limited
Solution Approach 1:
The patent introduces a new pharmacological parameter (COMT enzyme inhibition) that expands the available treatment options beyond existing medications. This novel mechanism of action provides an additional therapeutic dimension for treating impulse control disorders, particularly for patients who have not responded to conventional pharmaceuticals
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
COMT inhibitors like tolcapone demonstrate significant reduction in symptoms of pathological gambling and kleptomania, with improved cognitive flexibility and decision-making, as evidenced by clinical trials, offering a novel approach to treating previously treatment-resistant conditions.
Implementation Method 1
catechol-O-methyl-transferase inhibitors (COMT inhibitors) like tolcapone or entacapone, which regulate dopamine levels in the prefrontal cortex
Data Source
AI summary
The invention provides methods for treating impulse control disorders in patients with catechol-o-methyl-transferase inhibitors. The invention also provides methods for treating patients with obsessive compulsive disorders and substance addictions with catechol-o-methyl-transferase inhibitors.